TherVoyant has been supported through several grants from the NIH National Cancer Institute (NCI) and through Wisconsin’s SBIR Advance matching grant program. To date, we have not accepted outside funding from investors and we remain undiluted.
Items for Grant Support Section:
NIH/NCI SBIR Phase I: 2013-2014, $216k
NIH/NCI SBIR Phase II 2015-2016, $1.45M
Wisconsin Center for Technology Commercialization SBIR Advance Matching grants